Skip to content

Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma

Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05794737
Enrollment
60
Registered
2023-04-03
Start date
2021-01-01
Completion date
2024-06-30
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Inhibin Beta A, Colorectal Carcinoma, Immunohistochemistry

Brief summary

A retrospective observational study to evaluate immunohistochemical expression of Inhibin Beta A (INHBA) in 60 cases of Colorectal Carcinoma, and compare levels of its expression to different clinicopathological criteria.

Detailed description

Colorectal Carcinoma is an aggressive malignant epithelial tumor with an observable high incidence. Tumor invasion and metastasis to distant sites are two important issues which determine patient's outcome, so detecting novel biological markers that are involved in tumor proliferation and invasion with subsequent targeting by future medical drugs will positively improve patient's prognosis. Inhibin Beta A (INHBA) is a glycoprotein molecule that has a role in tumor cells proliferation and invasion in different human malignancies. The aim of this study is to detect expression of INHBA in 60 archived formalin-fixed Paraffin-embedded tissue blocks of patients suffered from Colorectal Carcinoma, and to correlate different levels of its expression to some studied clinical and pathological criteria (Age, Sex, Tumor size, location, depth of tumor invasion, status of regional lymph nodes, vascular and perineural invasion).

Interventions

Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
35 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Specimens from patients with Colorectal Carcinoma. Tissue blocks with sufficient material. Specimens with sufficient clinical data.

Exclusion criteria

Tissue blocks with insufficient, destroyed or necrotic material. Specimens with insufficient clinical data.

Design outcomes

Primary

MeasureTime frameDescription
Detection of INHBA in Colorectal Carcinoma.6 monthsDetection of expression of INHBA in Colorectal Carcinoma cells by immunohistochemical approach, using anti-human INHBA monoclonal antibody.

Secondary

MeasureTime frameDescription
Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.6 monthsCorrelation between different levels of INHBA expression in Colorectal Carcinoma cells and some clinical and pathological parameters as age, sex, tumor phenotype and nodal status.

Countries

Egypt

Contacts

Primary ContactMera A Fayez, Doctor
meraatef@med.sohag.edu.eg01224890136

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026